Not your average spec biotech for several reasons but one in particular is that RGS already has substantial revenues of around $2 million per annum
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025